What Is Metaplastic Breast Cancer? How Is It Treated?

Metaplastic breast cancer is a rare, fast-growing type of breast cancer that can spread anywhere in the body. Because of its aggressive growth and spread, it is often diagnosed at an advanced stage.
The World Health Organization (WHO) classified metaplastic breast cancer as a separate disease in 2000, and this subtype accounts for less than 1% of breast cancer cases.
In this article, we share the symptoms, diagnosis and treatment of metaplastic breast cancer.
What Is Metaplastic Breast Cancer?
The Greek term “metaplasia” means “a change in form.” Under a microscope, metaplastic breast cancer cells may look like a mixture of breast cells and other cells, for example:
- cartilage
- muscle
- bone
- skin
- connective tissue
The different shapes and characteristics of these cells tell pathologists the subtype of metaplastic breast cancer. The treatment approach is the same for all subtypes of metaplastic breast cancer.
Metaplastic breast cancer is an aggressive and invasive cancer, meaning it multiplies rapidly and can spread throughout the body. Compared with other breast cancers, it is more likely to spread to the lungs, or metastasize there.
What Are the Symptoms of Metaplastic Breast Cancer?
Many symptoms of metaplastic breast cancer are the same as those of other breast cancer types. Symptoms may include:
- a new breast lump, typically larger than in other breast cancers and usually more than 2 cm in size
- changes in breast shape and size
- dimple-like indentations in the skin of the breast
- nipple discharge other than breast milk
- a change in nipple position
- breast pain
A person with these symptoms should speak with a doctor as soon as possible.
- Related topic: What are the symptoms of breast cancer other than a palpable lump?
How Is Metaplastic Breast Cancer Diagnosed?
Breast cancer is diagnosed by biopsy. A sample of tumor tissue obtained in the biopsy undergoes certain procedures and is examined under a microscope by a specialist pathologist in a pathology laboratory. First, the pathologist determines whether the tumor tissue is cancerous. If cancer is identified, the next step is special staining to determine the breast cancer subtype; in medical terminology, these are called immunohistochemical stains.
Metaplastic breast cancer cells contain two or more cell types, and their appearance determines the subtype. Cell types seen in metaplastic breast cancer include:
- adenosquamous
- carcinosarcoma
- chondroid
- bony
- spindle cell
- squamous
In addition to identifying the subtype, a pathologist grades the cancer from 1-3. Grade 1 means the cancer cells grow relatively slowly, while grade 3 means they multiply more quickly and the cancer may spread faster.
Most people with metaplastic breast cancer have a grade 3 tumor when they receive their diagnosis.
Metaplastic Breast Cancer Has Biological Features Similar to Triple-Negative Breast Cancer
Many breast cancer cells have receptors for estrogen, progesterone or human epidermal growth factor receptor 2 (HER2). Whether the cancer cells have any of these receptors affects treatment options.
Most—but not all—metaplastic breast cancers lack all three of these receptors and are of the triple-negative type.
We use a staging system to determine whether cancer has spread and how much of the body it affects. Stages range from 0 to 4, with higher numbers meaning the cancer has spread further. Patients with metaplastic breast cancer generally have stage 2 or higher disease at diagnosis.
How Is Metaplastic Breast Cancer Treated?
Because metaplastic breast cancer is rare and has only recently been identified, we generally tend to treat it in the same way as other breast cancers. The oncologist will discuss treatment options with the patient, depending on the cancer's grade, stage and triple-negative status.
As with other breast cancers, local treatments such as surgery and radiotherapy, and systemic treatments such as chemotherapy and immunotherapy, are used in metaplastic breast cancer. Since it largely resembles triple-negative breast cancer, immunotherapy is a treatment option that must be kept in mind. Therefore, to test suitability for immunotherapy in patients with metaplastic breast cancer, PD-L1 and TMB tests should be considered. In addition, taxane chemotherapy is known to be more effective in metaplastic breast cancer than other chemotherapies.
Summary
Patients with metaplastic breast cancer have less favorable 5-year disease-specific survival rates than people with other breast cancers. A 2015 study conducted in Turkey found a 5-year survival rate of 93% for hormone-positive breast cancer, compared with 78% for metaplastic breast cancer. In fact, this study found lower survival rates for metaplastic breast cancer than for the triple-negative subtype.
Outcomes can also vary by metaplastic breast cancer subtype. The squamous subtype appears to have the lowest 5-year disease-specific survival rate, at 56%.
However, it is important to remember that these survival data come from the period before immunotherapy.
Research on metaplastic breast cancer and clinical studies investigating targeted treatments continue.
In conclusion:
- Metaplastic breast cancer is a rare, aggressive and invasive form of breast cancer. Most patients have stage 2 or more advanced disease at diagnosis.
- Because it does not respond well to standard treatments, outcomes are generally less favorable than for other breast cancer types. However, newer options, such as immunotherapy or targeted medicines, may improve outcomes in metaplastic breast cancer.
- Ongoing cancer treatment and support can help improve a person's quality of life.
Sources
https://journals.lww.com/md-journal/Fulltext/2015/12280/Metaplastic_Breast_Carcinoma_Versus.21.aspx
2. Boler, D. E., et al. (2016). Metaplastic carcinoma of the breast: A case series and review of the literature.
https://www.sciencedirect.com/science/article/pii/S2452336416300164
3. Breast biopsy. (2019).
https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html
4. Breast cancer. (2018).
https://medlineplus.gov/breastcancer.html
5. Breast cancer grades. (2019).
https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-grades.html
6. Breast cancer stages. (2021).
https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/stages-of-breast-cancer.html
7. Chiriac, V.-F., et al. (2018). Psychological stress and breast cancer incidence: A systematic review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808262
8. Coughlin, S. S., et al. (2020). Financial distress among breast cancer survivors.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518546
9. infrequent subtype of triple negative breast carcinoma.
https://www.mdpi.com/2072-6694/12/7/1832/htm
10. Schwartz, T. L., et al. (2013). Metaplastic breast cancer: Histologic characteristics, prognostic factors and systemic treatment strategies.
https://ehoonline.biomedcentral.com/articles/10.1186/2162-3619-2-31
11. Tadros, A. B., et al. (2021). Survival outcomes for metaplastic breast cancer differ by histologic subtype [Abstract].
https://link.springer.com/article/10.1245/s10434-020-09430-5
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.